tradingkey.logo

ANI Pharmaceuticals Inc

ANIP

97.480USD

+2.125+2.23%
終値 09/18, 16:00ET15分遅れの株価
2.12B時価総額
損失額直近12ヶ月PER

ANI Pharmaceuticals Inc

97.480

+2.125+2.23%
詳細情報 ANI Pharmaceuticals Inc 企業名
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
企業情報
企業コードANIP
会社名ANI Pharmaceuticals Inc
上場日May 04, 2000
最高経営責任者「CEO」Mr. Nikhil Suresh Lalwani
従業員数897
証券種類Ordinary Share
決算期末May 04
本社所在地210 Main Street West
都市BAUDETTE
証券取引所NASDAQ Global Market Consolidated
United States of America
郵便番号56623
電話番号12186343500
ウェブサイトhttps://www.anipharmaceuticals.com/
企業コードANIP
上場日May 04, 2000
最高経営責任者「CEO」Mr. Nikhil Suresh Lalwani
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
61.19K
-2.72%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
26.96K
+19.17%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
61.19K
-2.72%
収益内訳
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
株主
更新時刻: Sun, Aug 17
更新時刻: Sun, Aug 17
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.94%
The Vanguard Group, Inc.
5.87%
Meridian Venture Partners
4.68%
Millennium Management LLC
4.63%
Global Alpha Capital Management Ltd.
3.97%
他の
69.91%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.94%
The Vanguard Group, Inc.
5.87%
Meridian Venture Partners
4.68%
Millennium Management LLC
4.63%
Global Alpha Capital Management Ltd.
3.97%
他の
69.91%
種類
株主統計
比率
Investment Advisor
45.50%
Investment Advisor/Hedge Fund
22.33%
Hedge Fund
18.31%
Individual Investor
7.74%
Private Equity
4.68%
Research Firm
3.66%
Corporation
2.94%
Bank and Trust
1.72%
Pension Fund
1.64%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
505
24.45M
112.92%
-1.14M
2025Q1
511
24.19M
111.77%
-1.42M
2024Q4
489
23.75M
109.53%
-1.38M
2024Q3
473
23.30M
110.79%
+2.44M
2024Q2
446
19.77M
94.29%
-402.06K
2024Q1
424
18.72M
89.20%
-877.00K
2023Q4
409
18.10M
88.69%
-881.29K
2023Q3
396
18.38M
91.57%
-127.77K
2023Q2
370
17.73M
90.91%
+852.82K
2023Q1
341
15.70M
87.63%
-1.26M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
2.44M
11.27%
-89.22K
-3.53%
Mar 31, 2025
The Vanguard Group, Inc.
1.18M
5.44%
-132.90K
-10.14%
Mar 31, 2025
Meridian Venture Partners
1.16M
5.38%
-255.00K
-17.97%
Mar 11, 2025
Millennium Management LLC
1.12M
5.16%
+298.32K
+36.45%
May 30, 2025
Global Alpha Capital Management Ltd.
735.59K
3.4%
+111.04K
+17.78%
Mar 31, 2025
State Street Global Advisors (US)
714.57K
3.3%
-22.72K
-3.08%
Mar 31, 2025
Deep Track Capital LP
700.00K
3.23%
+50.96K
+7.85%
Mar 31, 2025
Esjay L.L.C,
632.62K
2.92%
-200.00K
-24.02%
Mar 14, 2025
Citadel Advisors LLC
723.33K
3.34%
+131.74K
+22.27%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
631.56K
2.92%
-54.17K
-7.90%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Sep 6
更新時刻: Sat, Sep 6
銘柄名
比率
SPDR S&P 600 Small Cap Growth ETF
0%
WisdomTree US SmallCap Fund
0%
SPDR Portfolio Small Cap ETF (SPSM)
0%
iShares U.S. Pharmaceuticals ETF
0%
iShares Core S&P Small-Cap ETF
0%
Invesco S&P SmallCap Health Care ETF
0%
Invesco Pharmaceuticals ETF
0%
Vanguard S&P Small-Cap 600 Growth Index Fund
0%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0%
SPDR S&P Pharmaceuticals ETF
0%
詳細を見る
SPDR S&P 600 Small Cap Growth ETF
比率0%
WisdomTree US SmallCap Fund
比率0%
SPDR Portfolio Small Cap ETF (SPSM)
比率0%
iShares U.S. Pharmaceuticals ETF
比率0%
iShares Core S&P Small-Cap ETF
比率0%
Invesco S&P SmallCap Health Care ETF
比率0%
Invesco Pharmaceuticals ETF
比率0%
Vanguard S&P Small-Cap 600 Growth Index Fund
比率0%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
比率0%
SPDR S&P Pharmaceuticals ETF
比率0%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI